Pharmacovigilance / Cardiovascular

((A-231)) (A-231) β-Blockers and Risk of Neuropsychiatric Adverse Events: An Active-Comparator Restricted Disproportionality on the FAERS

((B-247)) (B-247) Understanding the natural history of heart failure by ejection fraction: a systematic review of common comorbidities, readmission rates, and mortality rates

((B-248)) (B-248) Sacubitril-valsartan and Risk of Ototoxicity: A Disproportionality Analysis

((B-249)) (B-249) DARWIN EU® - Incidence of Myoclonus in Heart Failure: a Descriptive Analysis in Patients Treated with Sacubitril/Valsartan and Other Treatments

((B-250)) (B-250) Safety Assessment on the Risk of Liver Dysfunction by ACE Inhibitors utilizing the MID-NET® in Japan

((B-251)) (B-251) Andexanet Alfa and Potential Risk of Thrombotic Events